Navidea Biopharmaceuticals (NYSE:NAVB) Earns Sell Rating from Analysts at StockNews.com

Equities researchers at StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB) in a report released on Tuesday. The brokerage set a “sell” rating on the stock.

Navidea Biopharmaceuticals Stock Performance

Shares of NAVB opened at $0.00 on Tuesday. Navidea Biopharmaceuticals has a 12-month low of $0.00 and a 12-month high of $0.15. The company has a market cap of $100,084.00, a P/E ratio of -0.02 and a beta of 1.49.

About Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.